3-37040291-T-C
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The NM_000249.4(MLH1):c.1664T>C(p.Leu555Pro) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. L555Q?) has been classified as Pathogenic.
Frequency
Consequence
NM_000249.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 29
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Colorectal cancer, hereditary nonpolyposis, type 2 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Jul 21, 2023 | This variant is considered likely pathogenic. Functional studies indicate this variant impacts protein function [PMID: 23712482, 30504929, 31784484]. This variant is expected to disrupt protein structure [Myriad internal data]. - |
Lynch syndrome Pathogenic:1
Likely pathogenic, reviewed by expert panel | curation | International Society for Gastrointestinal Hereditary Tumours (InSiGHT) | Jun 21, 2019 | Multifactorial likelihood analysis posterior probability 0.95-0.99 - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 01, 2019 | The p.L555P pathogenic mutation (also known as c.1664T>C), located in coding exon 14 of the MLH1 gene, results from a T to C substitution at nucleotide position 1664. The leucine at codon 555 is replaced by proline, an amino acid with similar properties. This alteration has been identified in individuals that met Amsterdam criteria for Lynch syndrome and their tumors demonstrated loss of both MLH1 and PMS2 on immunohistochemistry (IHC) (Ambry internal data; Farrell MP et al. Fam. Cancer, 2013 Dec;12:741-7). In an in vitro complementation assay, this variant demonstrated mismatch repair (MMR) activity similar to a known pathogenic mutation (Farrell MP et al. Fam. Cancer, 2013 Dec;12:741-7). Another alteration at the same position, p.L555R, has been reported as pathogenic due to its strong segregation with disease in a Lynch syndrome family with several individuals demonstrating high microsatellite instability (MSI-H) or loss of MLH1 and PMS2 on IHC in their tumors (Ambry internal data; Haraldsdottir S et al. Fam. Cancer, 2016 Apr;15:253-60; Roth RM et al. Am. J. Clin. Pathol., 2016 Jul;146:50-6; Haraldsdottir S et al. Genet. Med., 2016 Sep;18:863-8). Based on an internal structural assessment, p.L555P is anticipated to decrease protein stability. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at